Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan-Dec:23:15330338241273324.
doi: 10.1177/15330338241273324.

Evaluation of the Effect of Radiosurgery for Target and Non-Target Lesions in Patients with Brain Metastases Using RANO-BM Criteria

Veselin Popov  1   2 , Gabriela Raycheva  1   2 , Vasko Graklanov  3   2 , Petar Uchikov  4   2 , Zhanet Grudeva-Popova  1   2
Affiliations

Evaluation of the Effect of Radiosurgery for Target and Non-Target Lesions in Patients with Brain Metastases Using RANO-BM Criteria

Veselin Popov et al. Technol Cancer Res Treat. 2024 Jan-Dec.

Abstract

Objectives: The current therapeutic indications of radiosurgery are constantly expanding. Magnetic resonance imaging (MRI) has an important role in the diagnostic and post-therapeutic period of primary and secondary brain tumor formations.

Methods: A total of 66 patients with verified cancer disease and brain metastases were separated into two groups. The first group includes 34 patients with primary non-small cell lung cancer and the second one 32 patients with other types of primary cancer. All of them received high-dose radiotherapy in 1-5 fractions. The number, size, and location of the treated lesions responded to robotic stereotactic radiosurgery criteria. The Response Assessment Criteria for Brain Metastases (RANO-BM) is an international multidisciplinary group of experts who developed acceptable criteria for assessing brain metastases. Before treatment and on the first, third, sixth month after radiosurgery, a MRI and blood tests were performed.

Results: Treated lesions were separated into four groups depending on the results - complete response, partial response, progressive disease, and stable disease. In both groups of patients, the percentage of complete or partial response had increased in the third and sixth months.

Conclusion: The results give us a reason not to recommend an MRI 1 month after treatment if the patient doesn't have any new neurological symptoms, because there may be a pseudo-progression. MRI results valued by RANO-BM criteria give us a good option to evaluate brain metastases on the third and sixth month after after stereotactic radiosurgery.

Keywords: CyberKnife; MRI; RANO-BM criteria; brain metastases; stereotactic radiosurgery.

PubMed Disclaimer

Conflict of interest statement

Declaration of Conflicting InterestsThe authors declared no potential conflicts of interest with respect to the research, authorship, and/or publication of this article.

Figures

Figure 1.
Figure 1.
Results of dynamic monitoring of targeted brain metastases in patients with NSCLC.
Figure 2.
Figure 2.
Results of dynamic monitoring of targeted brain metastases in patients with OTPC.
Figure 3.
Figure 3.
Results of dynamic monitoring of newly diagnosed (non-target) brain metastases in patients with NSCLC.
Figure 4.
Figure 4.
Results of the dynamic monitoring of newly diagnosed (non-target) brain metastases in patients with OTPC.
See this image and copyright information in PMC

References

    1. Валерианова З. Заболяемост от рак в България. Български национален раков регистър. Том XXIV, 2017.
    1. American Cancer Society. Cancer Facts & Figures 2019. https:// www.cancer.org/ content/dam/cancer-org/research/cancer-facts-an....
    1. Siegel R, Miller K, Jemal A. Cancer statistics 2020. CA Cancer J Clin. 2020;1(70):1-24. - PubMed
    1. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: Sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136(5):E359-E386. doi:10.1002/ijc.29210 - DOI - PubMed
    1. Couraud S, Souquet P, Paris C, et al. BioCAST/IFCT-1002: Epidemiological and molecular features of lung cancer in never-smokers. Eur Respir J. 2015;45(5):1403-1414. - PubMed

LinkOut - more resources